Price movement over the last 24 hours
AdaptHealth Corp vs Kimberly Clark Corp — how do they compare? AdaptHealth Corp trades at $10.05 (market cap $1.38B), while Kimberly Clark Corp trades at $111.55 (market cap $38.09B). The key difference: Kimberly Clark Corp is far larger — about 27.6× AdaptHealth Corp's market cap, and Kimberly Clark Corp pays a 4.46% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | KMB | |
|---|---|---|
Market Cap | $1.38B | $38.09B |
Sector | Health | Consumer Staples |
52-Week High | $13.38 | $136.77 |
52-Week Low | $8.68 | $93.05 |
Enterprise Value | $3.33B | $44.63B |
Dividend Yield | — | 4.46% |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
Kimberly-Clark (KMB) trades at $114.74, up 0.02% on the day, showing stable performance near its consensus price target. The stock maintains a bullish technical signal with strong moving average support, though oscillators indicate potential overbought conditions. Fundamentally, the company demonstrates consistent earnings beats with Q1 2026 EPS of $1.97 exceeding expectations, supported by a healthy 12.8% net income margin and robust ROE of 146.29%. Recent corporate actions include a $1.28 dividend payment scheduled for July 2026.
KMB presents a mixed outlook with strong profitability metrics offset by revenue declines from $20.4B in 2023 to $16.45B in 2025. Investment appeal includes a 5%+ dividend yield and analyst consensus leaning toward Hold (58.06%) with a $109.20 price target. Key risks include margin pressure from input costs and competitive threats from new market entrants like Arbex. Institutional sentiment remains cautious despite technical strength, requiring monitoring of Q2 2026 earnings due August 4, 2026.
Trailing returns across standard periods
Latest headlines on both assets
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →